Optimization of synergistic combination regimens against carbapenem- and aminoglycoside-resistant clinical Pseudomonas aeruginosa isolates via mechanism-based pharmacokinetic/pharmacodynamic modeling

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 1, 2017, Pages

  Yadav, Rajbharan ^a   Bulitta, Jürgen B ^b   Nation, Roger L ^a   Landersdorfer, Cornelia B ^a,c,d  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF FLORIDA   (United States)

^c MONASH UNIVERSITY   (Australia)

^d UNIVERSITY AT BUFFALO   (United States)

Author keywords

Amikacin; Imipenem; Mathematical modeling; Monte Carlo simulations; Population pharmacokinetics and pharmacodynamics; Synergy; Tobramycin

Indexed keywords

AMIKACIN; IMIPENEM; TOBRAMYCIN; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CONCENTRATION AT STEADY-STATE; CONTINUOUS INFUSION; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DRUG DOSE REGIMEN; DRUG POTENTIATION; HUMAN; LOADING DRUG DOSE; MATHEMATICAL MODEL; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MUTATION RATE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; MONTE CARLO METHOD; THEORETICAL MODEL;

AMIKACIN; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CARBAPENEMS; DRUG SYNERGISM; IMIPENEM; MICROBIAL SENSITIVITY TESTS; MODELS, THEORETICAL; MONTE CARLO METHOD; PSEUDOMONAS AERUGINOSA; TOBRAMYCIN;

EID: 85009250590     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01011-16     Document Type: Article

References (74)

1. Boucher HW, Talbot GH, Benjamin DK, Jr, Bradley J, Guidos RJ, Jones RN, Murray BE, Bonomo RA, Gilbert D. 2013. 10 x ′20 progress - development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis 56:1685-1694. https://doi.org/10.1093/cid/cit152.
2. Infectious Diseases Society of America, Spellberg B, Blaser M, Guidos RJ, Boucher HW, Bradley JS, Eisenstein BI, Gerding D, Lynfield R, Reller LB, Rex J, Schwartz D, Septimus E, Tenover FC, Gilbert DN. 2011. Combating antimicrobial resistance: policy recommendations to save lives. Clin Infect Dis 52(Suppl 5):S397-S428. https://doi.org/10.1093/cid/cir153.
3. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. 2007. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 6:29-40. https://doi.org/10.1038/nrd2201.
4. Walker B, Barrett S, Polasky S, Galaz V, Folke C, Engstrom G, Ackerman F, Arrow K, Carpenter S, Chopra K, Daily G, Ehrlich P, Hughes T, Kautsky N, Levin S, Maler KG, Shogren J, Vincent J, Xepapadeas T, de Zeeuw A. 2009. Environment. Looming global-scale failures and missing institutions. Science 325:1345-1346. https://doi.org/10.1126/science.1175325.
5. Dantas RC, Ferreira ML, Gontijo-Filho PP, Ribas RM. 2014. Pseudomonas aeruginosa bacteraemia: independent risk factors for mortality and impact of resistance on outcome. J Med Microbiol 63:1679-1687. https://doi.org/10.1099/jmm.0.073262-0.
6. Woodford N, Turton JF, Livermore DM. 2011. Multiresistant Gram-negative bacteria: the role of high-risk clones in the dissemination of antibiotic resistance. FEMS Microbiol Rev 35:736-755. https://doi.org/10.1111/j.1574-6976.2011.00268.x.
7. Partridge SR. 2011. Analysis of antibiotic resistance regions in Gram-negative bacteria. FEMS Microbiol Rev 35:820-855. https://doi.org/10.1111/j.1574-6976.2011.00277.x.
8. Louie A, Liu W, Fikes S, Brown D, Drusano GL. 2013. Impact of meropenem in combination with tobramycin in a murine model of Pseudomonas aeruginosa pneumonia. Antimicrob Agents Chemother 57:2788-2792. https://doi.org/10.1128/AAC.02624-12.
9. Zavascki AP, Bulitta JB, Landersdorfer CB. 2013. Combination therapy for carbapenem-resistant Gram-negative bacteria. Expert Rev Anti Infect Ther 11:1333-1353. https://doi.org/10.1586/14787210.2013.845523.
10. Lee CS, Doi Y. 2014. Therapy of infections due to carbapenem-resistant Gram-negative pathogens. Infect Chemother 46:149-164. https://doi.org/10.3947/ic.2014.46.3.149.
11. Kresken M, Korber-Irrgang B, Lauffer J, Decker-Burgard S, Davies T. 2011. In vitro activities of ceftobiprole combined with amikacin or levofloxacin against Pseudomonas aeruginosa: evidence of a synergistic effect using time-kill methodology. Int J Antimicrob Agents 38:70-75. https://doi.org/10.1016/j.ijantimicag.2011.01.028.
12. Milatovic D, Braveny I. 1987. Development of resistance during antibiotic therapy. Eur J Clin Microbiol 6:234-244. https://doi.org/10.1007/BF02017607.
13. Drusano GL, Liu W, Fregeau C, Kulawy R, Louie A. 2009. Differing effects of combination chemotherapy with meropenem and tobramycin on cell kill and suppression of resistance of wild-type Pseudomonas aeruginosa PAO1 and its isogenic MexAB efflux pump-overexpressed mutant. Antimicrob Agents Chemother 53:2266-2273. https://doi.org/10.1128/AAC.01680-08.
14. Tam VH, Schilling AN, Lewis RE, Melnick DA, Boucher AN. 2004. Novel approach to characterization of combined pharmacodynamic effects of antimicrobial agents. Antimicrob Agents Chemother 48:4315-4321. https://doi.org/10.1128/AAC.48.11.4315-4321.2004.
15. Tam VH, Schilling AN, Neshat S, Poole K, Melnick DA, Coyle EA. 2005. Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa. Antimicrob Agents Chemother 49:4920-4927. https://doi.org/10.1128/AAC.49.12.4920-4927.2005.
16. Lim TP, Lee W, Tan TY, Sasikala S, Teo J, Hsu LY, Tan TT, Syahidah N, Kwa AL. 2011. Effective antibiotics in combination against extreme drug-resistant Pseudomonas aeruginosa with decreased susceptibility to polymyxin B. PLoS One 6:e28177. https://doi.org/10.1371/journal.pone.0028177.
17. Ly NS, Bulitta JB, Rao GG, Landersdorfer CB, Holden PN, Forrest A, Bergen PJ, Nation RL, Li J, Tsuji BT. 2015. Colistin and doripenem combinations against Pseudomonas aeruginosa: profiling the time course of synergistic killing and prevention of resistance. J Antimicrob Chemother 70:1434-1442. https://doi.org/10.1093/jac/dku567.
18. Loh B, Grant C, Hancock RE. 1984. Use of the fluorescent probe 1-N-phenylnaphthylamine to study the interactions of aminoglycoside antibiotics with the outer membrane of Pseudomonas aeruginosa. Antimicrob Agents Chemother 26:546-551. https://doi.org/10.1128/AAC.26.4.546.
19. Yadav R, Landersdorfer CB, Nation RL, Boyce JD, Bulitta JB. 2015. Novel approach to optimize synergistic carbapenem-aminoglycoside combinations against carbapenem-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 59:2286-2298. https://doi.org/10.1128/AAC.04379-14.
20. Anan N, Toba S, Ito A, Nakamura R, Tsuji M. 2011. In vitro combination effects of doripenem with aminoglycoside or ciprofloxacin against Pseudomonas aeruginosa. Jpn J Antibiot 64:203-216.
21. Balke B, Hogardt M, Schmoldt S, Hoy L, Weissbrodt H, Haussler S. 2006. Evaluation of the E test for the assessment of synergy of antibiotic combinations against multiresistant Pseudomonas aeruginosa isolates from cystic fibrosis patients. Eur J Clin Microbiol Infect Dis 25:25-30. https://doi.org/10.1007/s10096-005-0076-9.
22. Gerceker AA, Gurler B. 1995. In-vitro activities of various antibiotics, alone and in combination with amikacin against Pseudomonas aeruginosa. J Antimicrob Chemother 36:707-711. https://doi.org/10.1093/jac/36.4.707.
23. Giamarellou H. 1986. Aminoglycosides plus beta-lactams against gram-negative organisms. Evaluation of in vitro synergy and chemical interactions. Am J Med 80:126-137.
24. Nakamura A, Hosoda M, Kato T, Yamada Y, Itoh M, Kanazawa K, Nouda H. 2000. Combined effects of meropenem and aminoglycosides on Pseudomonas aeruginosa in vitro. J Antimicrob Chemother 46:901-904. https://doi.org/10.1093/jac/46.6.901.
25. Tasaka K, Ishida A, Chinzei T. 2002. Antimicrobial activity of carbapenems and the combined effect with aminoglycoside against recent clinical isolates of Pseudomonas aeruginosa. Jpn J Antibiot 55:181-186. https://doi.org/10.7164/antibiotics.55.181.
26. Yamashiro Y, Ogake N, Takahata M, Minami S. 2000. In vitro interaction of piperacillin and imipenem/cilastatin combined with aminoglycosides against Pseudomonas aeruginosa. Jpn J Antibiot 53:194-200.
27. Niida M, Sakakibara S, Kawabata T, Maebashi K, Takata T, Hikida M. 2004. Combined effects of arbekacin with biapenem against in vitro and in vivo model of a mixture of MRSA and Pseudomonas aeruginosa. Jpn J Antibiot 57:288-293.
28. Wise R, Ashby JP, Andrews JM. 1989. The antibacterial activity of meropenem in combination with gentamicin or vancomycin. J Antimicrob Chemother 24(Suppl A):233-238. https://doi.org/10.1093/jac/24.suppl-A.233.
29. Ulrich E, Trautmann M, Krause B, Bauernfeind A, Hahn H. 1989. Comparative efficacy of ciprofloxacin, azlocillin, imipenem/cilastatin and tobramycin in a model of experimental septicemia due to Pseudomonas aeruginosa in neutropenic mice. Infection 17:311-315. https://doi.org/10.1007/BF01650716.
30. Landersdorfer CB, Ly NS, Xu H, Tsuji BT, Bulitta JB. 2013. Quantifying subpopulation synergy for antibiotic combinations via mechanism-based modeling and a sequential dosing design. Antimicrob Agents Chemother 57:2343-2351. https://doi.org/10.1128/AAC.00092-13.
31. Kadurugamuwa JL, Clarke AJ, Beveridge TJ. 1993. Surface action of gentamicin on Pseudomonas aeruginosa. J Bacteriol 175:5798-5805.
32. Kadurugamuwa JL, Lam JS, Beveridge TJ. 1993. Interaction of gentamicin with the A band and B band lipopolysaccharides of Pseudomonas aeruginosa and its possible lethal effect. Antimicrob Agents Chemother 37:715-721. https://doi.org/10.1128/AAC.37.4.715.
33. Obara M, Nakae T. 1991. Mechanisms of resistance to beta-lactam antibiotics in Acinetobacter calcoaceticus. J Antimicrob Chemother 28:791-800. https://doi.org/10.1093/jac/28.6.791.
34. Sato K, Nakae T. 1991. Outer membrane permeability of Acinetobacter calcoaceticus and its implication in antibiotic resistance. J Antimicrob Chemother 28:35-45. https://doi.org/10.1093/jac/28.1.35.
35. Bulitta JB, Ly NS, Landersdorfer CB, Wanigaratne NA, Velkov T, Yadav R, Oliver A, Martin L, Shin BS, Forrest A, Tsuji BT. 2015. Two mechanisms of killing of Pseudomonas aeruginosa by tobramycin assessed at multiple inocula via mechanism-based modeling. Antimicrob Agents Chemother 59:2315-2327. https://doi.org/10.1128/AAC.04099-14.
36. Conil JM, Georges B, Ruiz S, Rival T, Seguin T, Cougot P, Fourcade O, Houin G, Saivin S. 2011. Tobramycin disposition in ICU patients receiving a once daily regimen: population approach and dosage simulations. Br J Clin Pharmacol 71:61-71. https://doi.org/10.1111/j.1365-2125.2010.03793.x.
37. Sakka SG, Glauner AK, Bulitta JB, Kinzig-Schippers M, Pfister W, Drusano GL, Sorgel F. 2007. Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial. Antimicrob Agents Chemother 51:3304-3310. https://doi.org/10.1128/AAC.01318-06.
38. Drusano GL, Liu W, Fikes S, Cirz R, Robbins N, Kurhanewicz S, Rodriquez J, Brown D, Baluya D, Louie A. 2014. Interaction of drug- and granulocyte-mediated killing of Pseudomonas aeruginosa in a murine pneumonia model. J Infect Dis 210:1319-1324. https://doi.org/10.1093/infdis/jiu237.
39. Kumar A, Haery C, Paladugu B, Kumar A, Symeoneides S, Taiberg L, Osman J, Trenholme G, Opal SM, Goldfarb R, Parrillo JE. 2006. The duration of hypotension before the initiation of antibiotic treatment is a critical determinant of survival in a murine model of Escherichia coli septic shock: association with serum lactate and inflammatory cytokine levels. J Infect Dis 193:251-258. https://doi.org/10.1086/498909.
40. Vazquez-Grande G, Kumar A. 2015. Optimizing antimicrobial therapy of sepsis and septic shock: focus on antibiotic combination therapy. Semin Respir Crit Care Med 36:154-166. https://doi.org/10.1055/s-0034-1398742.
41. Matar KM, Al-Lanqawi Y, Abdul-Malek K, Jelliffe R. 2013. Amikacin population pharmacokinetics in critically ill Kuwaiti patients. Biomed Res Int 2013:202818. https://doi.org/10.1155/2013/202818.
42. Roberts JA, Lipman J. 2009. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 37:840-851. https://doi.org/10.1097/CCM.0b013e3181961bff.
43. Tod M, Padoin C, Petitjean O. 2000. Clinical pharmacokinetics and pharmacodynamics of isepamicin. Clin Pharmacokinet 38:205-223. https://doi.org/10.2165/00003088-200038030-00002.
44. Cannon JP, Lee TA, Clark NM, Setlak P, Grim SA. 2014. The risk of seizures among the carbapenems: a meta-analysis. J Antimicrob Chemother 69:2043-2055. https://doi.org/10.1093/jac/dku111.
45. Koppel BS, Hauser WA, Politis C, van Duin D, Daras M. 2001. Seizures in the critically ill: the role of imipenem. Epilepsia 42:1590-1593.
46. Szczygiel B, Pertkiewicz M, Meszaros J, Otto M, Grochowiecki T, Rudnicka J, Hacel I, Solecka-Lasak M. 1992. Imipenem in the treatment of patients with severe surgical infection. Pol Tyg Lek 47:638-641.
47. Patel BM, Paratz J, See NC, Muller MJ, Rudd M, Paterson D, Briscoe SE, Ungerer J, McWhinney BC, Lipman J, Roberts JA. 2012. Therapeutic drug monitoring of beta-lactam antibiotics in burns patients - a one-year prospective study. Ther Drug Monit 34:160-164. https://doi.org/10.1097/FTD.0b013e31824981a6.
48. Pea F, Cojutti P, Sbrojavacca R, Cadeo B, Cristini F, Bulfoni A, Furlanut M. 2011. TDM-guided therapy with daptomycin and meropenem in a morbidly obese, critically ill patient. Ann Pharmacother 45:e37. https://doi.org/10.1345/aph.1P745.
49. Clinical and Laboratory Standards Institute. 2015. Performance standards for antimicrobial susceptibility testing: 25th informational supplement. M100-S25. CLSI, Wayne, PA.
50. European Committee on Antimicrobial Susceptibility Testing. 2015. Breakpoint tables for interpretation of MICs and zone diameters, version 5.0. http://www.eucast.org/clinical-breakpoints/.
51. Taccone FS, Laterre PF, Spapen H, Dugernier T, Delattre I, Layeux B, De Backer D, Wittebole X, Wallemacq P, Vincent JL, Jacobs F. 2010. Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock. Crit Care 14:R53. https://doi.org/10.1186/cc8945.
52. Bulitta JB, Yang JC, Yohonn L, Ly NS, Brown SV, D'Hondt RE, Jusko WJ, Forrest A, Tsuji BT. 2010. Attenuation of colistin bactericidal activity by high inoculum of Pseudomonas aeruginosa characterized by a new mechanism-based population pharmacodynamic model. Antimicrob Agents Chemother 54:2051-2062. https://doi.org/10.1128/AAC.00881-09.
53. Nicasio AM, Bulitta JB, Lodise TP, D'Hondt RE, Kulawy R, Louie A, Drusano GL. 2012. Evaluation of once-daily vancomycin against methicillin-resistant Staphylococcus aureus in a hollow-fiber infection model. Antimicrob Agents Chemother 56:682-686. https://doi.org/10.1128/AAC.05664-11.
54. Konig C, Simmen HP, Blaser J. 1998. Bacterial concentrations in pus and infected peritoneal fluid - implications for bactericidal activity of antibiotics. J Antimicrob Chemother 42:227-232. https://doi.org/10.1093/jac/42.2.227.
55. LaPlante KL, Rybak MJ. 2004. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 48:4665-4672. https://doi.org/10.1128/AAC.48.12.4665-4672.2004.
56. Lee S, Kwon KT, Kim HI, Chang HH, Lee JM, Choe PG, Park WB, Kim NJ, Oh MD, Song DY, Kim SW. 2014. Clinical implications of cefazolin inoculum effect and b-lactamase type on methicillin-susceptible Staphylococcus aureus bacteremia. Microb Drug Resist 20:568-574. https://doi.org/10.1089/mdr.2013.0229.
57. Li J, Echevarria KL, Hughes DW, Cadena JA, Bowling JE, Lewis JS, II. 2014. Comparison of cefazolin versus oxacillin for treatment of complicated bacteremia caused by methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother 58:5117-5124. https://doi.org/10.1128/AAC.02800-14.
58. Rose WE, Leonard SN, Rossi KL, Kaatz GW, Rybak MJ. 2009. Impact of inoculum size and heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) on vancomycin activity and emergence of VISA in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 53:805-807. https://doi.org/10.1128/AAC.01009-08.
59. So W, Crandon JL, Zhanel GG, Nicolau DP. 2014. Comparison of in vivo and in vitro pharmacodynamics of a humanized regimen of 600 milligrams of ceftaroline fosamil every 12 hours against Staphylococcus aureus at initial inocula of 106 and 108 CFU per milliliter. Antimicrob Agents Chemother 58:6931-6933. https://doi.org/10.1128/AAC.03652-14.
60. Louie A, Bied A, Fregeau C, Van Scoy B, Brown D, Liu W, Bush K, Queenan AM, Morrow B, Khashab M, Kahn JB, Nicholson S, Kulawy R, Drusano GL. 2010. Impact of different carbapenems and regimens of administration on resistance emergence for three isogenic Pseudomonas aeruginosa strains with differing mechanisms of resistance. Antimicrob Agents Chemother 54:2638-2645. https://doi.org/10.1128/AAC.01721-09.
61. Bulitta JB, Ly NS, Yang JC, Forrest A, Jusko WJ, Tsuji BT. 2009. Development and qualification of a pharmacodynamic model for the pronounced inoculum effect of ceftazidime against Pseudomonas aeruginosa. Antimicrob Agents Chemother 53:46-56. https://doi.org/10.1128/AAC.00489-08.
62. Cheah SE, Li J, Tsuji BT, Forrest A, Bulitta JB, Nation RL. 2016. Colistin and polymyxin B dosage regimens against Acinetobacter baumannii: differences in activity and the emergence of resistance. Antimicrob Agents Chemother 60:3921-3933. https://doi.org/10.1128/AAC.02927-15.
63. Jacobs M, Gregoire N, Couet W, Bulitta JB. 2016. Distinguishing antimicrobial models with different resistance mechanisms via population pharmacodynamic modeling. PLoS Comput Biol 12:e1004782. https://doi.org/10.1371/journal.pcbi.1004782.
64. Maidhof H, Johannsen L, Labischinski H, Giesbrecht P. 1989. Onset of penicillin-induced bacteriolysis in staphylococci is cell cycle dependent. J Bacteriol 171:2252-2257. https://doi.org/10.1128/jb.171.4.2252-2257.1989.
65. Tsuji BT, Bulitta JB, Brown T, Forrest A, Kelchlin PA, Holden PN, Peloquin CA, Skerlos L, Hanna D. 2012. Pharmacodynamics of early, high-dose linezolid against vancomycin-resistant enterococci with elevated MICs and pre-existing genetic mutations. J Antimicrob Chemother 67:2182-2190. https://doi.org/10.1093/jac/dks201.
66. Bauer RJ, Guzy S, Ng C. 2007. A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples. AAPS J 9:E60-E83. https://doi.org/10.1208/aapsj0901007.
67. Bulitta JB, Bingolbali A, Shin BS, Landersdorfer CB. 2011. Development of a new pre- and post-processing tool (SADAPT-TRAN) for nonlinear mixed-effects modeling in S-ADAPT. AAPS J 13:201-211. https://doi.org/10.1208/s12248-011-9257-x.
68. Bulitta JB, Landersdorfer CB. 2011. Performance and robustness of the Monte Carlo importance sampling algorithm using parallelized S-ADAPT for basic and complex mechanistic models. AAPS J 13:212-226. https://doi.org/10.1208/s12248-011-9258-9.
69. Bulitta JB, Duffull SB, Kinzig-Schippers M, Holzgrabe U, Stephan U, Drusano GL, Sorgel F. 2007. Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers. Antimicrob Agents Chemother 51:2497-2507. https://doi.org/10.1128/AAC.01477-06.
70. Bulitta JB, Zhao P, Arnold RD, Kessler DR, Daifuku R, Pratt J, Luciano G, Hanauske AR, Gelderblom H, Awada A, Jusko WJ. 2009. Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients. Cancer Chemother Pharmacol 63:1049-1063. https://doi.org/10.1007/s00280-008-0827-2.
71. Tsuji BT, Okusanya OO, Bulitta JB, Forrest A, Bhavnani SM, Fernandez PB, Ambrose PG. 2011. Application of pharmacokinetic-pharmacodynamic modeling and the justification of a novel fusidic acid dosing regimen: raising Lazarus from the dead. Clin Infect Dis 52(Suppl 7):S513-S519. https://doi.org/10.1093/cid/cir166.
72. Landersdorfer CB, Kirkpatrick CM, Kinzig-Schippers M, Bulitta JB, Holzgrabe U, Drusano GL, Sorgel F. 2007. Population pharmacokinetics at two dose levels and pharmacodynamic profiling of flucloxacillin. Antimicrob Agents Chemother 51:3290-3297. https://doi.org/10.1128/AAC.01410-06.
73. Drusano GL, Liu W, Kulawy R, Louie A. 2011. Impact of granulocytes on the antimicrobial effect of tedizolid in a mouse thigh infection model. Antimicrob Agents Chemother 55:5300-5305. https://doi.org/10.1128/AAC.00502-11.
74. Yadav R, Bulitta JB, Nation RL, Landersdorfer CB. 2016. Optimization of synergistic combinations against carbapenem- and aminoglycoside-resistant clinical isolates of Pseudomonas aeruginosa via mechanism-based modelling, poster 504. ASM Microbe 2016, Boston, MA, USA, 16 to 20 June, 2016.